TY  - JOUR
TI  - Brodalumab
AB  - Brodalumab is a human monoclonal antibody that inhibits interleukin-17 (IL-17) pathway by binding to IL-17 receptor. In clinical trials, a PASI75 
response has been achieved in 82-84% of the patients at week 12. It was shown to be effective also in generalized pustular and erythrodermic 
psoriasis. As with other IL-17 inhibitors, brodalumab should be used with caution in patients with inflammatory bowel disease.
AU  - borlu, murat
DO  - 10.4274/turkderm.galenos.2022.01643
PY  - 2022
JO  - Türkderm Türk deri hastalıkları ve frengi arşivi
VL  - 56
IS  - 1
SN  - 2717-6398
SP  - 58
EP  - 60
DB  - TRDizin
UR  - http://search/yayin/detay/534078
ER  -